NCT06899763Completed
Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy
Source: ClinicalTrials.gov · Last updated 28 Mar 2025
Brief summary (registry, in English)
The goal of this observational study is to learn about the the immune landscape of HCC arising from different etiology, such as MASLD and viral hepatitis, at single cell level. The main question it aims to answer is: Which are the immune signatures and pathways linked to MASLD- or virus-related HCC and what could be the best targets for immunotherapy?
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 6 (actual)
- First submitted
- 21 Mar 2025
- Start date
- 1 Jan 2023
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06899763
What you commit to
- Study type: Observational
- Participants enrolled: 6
- From 1 Jan 2023 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- HCV-related HCC or MASLD-related HCC
- age: ≥ 18 years, ≤ 90 years
- Signature of the informed consent
- Esclusion criteria:
- Concomitant pathologies with a life expectancy of less than 12 months
- Autoimmune or chronic inflammatory diseases
- Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors, tyrosine kinase inhibitors, or anti-VEGF therapies
- Other ongoing extrahepatic malignancies or those diagnosed within the last 3 years, except for tumors resected with curative intent and with no evidence of disease recurrence for \>3 years prior to the signing of informed consent, and considered at low risk of recurrence
- HIV infection
- Lack of patient cooperation and failure to sign the informed consent
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo di Pavia Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.